BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 18924149)

  • 1. Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models.
    Pham NA; Magalhaes JM; Do T; Schwock J; Dhani N; Cao PJ; Hill RP; Hedley DW
    Int J Cancer; 2009 Jan; 124(2):280-6. PubMed ID: 18924149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
    Rajeshkumar NV; Tan AC; De Oliveira E; Womack C; Wombwell H; Morgan S; Warren MV; Walker J; Green TP; Jimeno A; Messersmith WA; Hidalgo M
    Clin Cancer Res; 2009 Jun; 15(12):4138-46. PubMed ID: 19509160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
    Schweppe RE; Kerege AA; French JD; Sharma V; Grzywa RL; Haugen BR
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2199-203. PubMed ID: 19293266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.
    Gray MJ; Zhang J; Ellis LM; Semenza GL; Evans DB; Watowich SS; Gallick GE
    Oncogene; 2005 Apr; 24(19):3110-20. PubMed ID: 15735682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
    Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
    Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth.
    Chang LC; Huang CH; Cheng CH; Chen BH; Chen HC
    J Biomed Sci; 2005; 12(4):571-85. PubMed ID: 16132110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
    Hiscox S; Jordan NJ; Smith C; James M; Morgan L; Taylor KM; Green TP; Nicholson RI
    Breast Cancer Res Treat; 2009 May; 115(1):57-67. PubMed ID: 18493848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
    Pathania D; Kuang Y; Sechi M; Neamati N
    Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Src/STAT3 signaling pathways are involved in KAI1-induced downregulation of VEGF-C expression in pancreatic cancer.
    Liu X; Guo X; Li H; Chen J; Qi X
    Mol Med Rep; 2016 Jun; 13(6):4774-8. PubMed ID: 27082851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts.
    Vukovic V; Haugland HK; Nicklee T; Morrison AJ; Hedley DW
    Cancer Res; 2001 Oct; 61(20):7394-8. PubMed ID: 11606368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nobiletin Inhibits Angiogenesis by Regulating Src/FAK/STAT3-Mediated Signaling through PXN in ER⁺ Breast Cancer Cells.
    Sp N; Kang DY; Joung YH; Park JH; Kim WS; Lee HK; Song KD; Park YM; Yang YM
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
    Green TP; Fennell M; Whittaker R; Curwen J; Jacobs V; Allen J; Logie A; Hargreaves J; Hickinson DM; Wilkinson RW; Elvin P; Boyer B; Carragher N; Plé PA; Bermingham A; Holdgate GA; Ward WH; Hennequin LF; Davies BR; Costello GF
    Mol Oncol; 2009 Jun; 3(3):248-61. PubMed ID: 19393585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
    Purnell PR; Mack PC; Tepper CG; Evans CP; Green TP; Gumerlock PH; Lara PN; Gandara DR; Kung HJ; Gautschi O
    J Thorac Oncol; 2009 Apr; 4(4):448-54. PubMed ID: 19240653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer.
    Lin SY; Chang HH; Lai YH; Lin CH; Chen MH; Chang GC; Tsai MF; Chen JJ
    PLoS One; 2015; 10(5):e0123305. PubMed ID: 25955608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD24 controls Src/STAT3 activity in human tumors.
    Bretz NP; Salnikov AV; Perne C; Keller S; Wang X; Mierke CT; Fogel M; Erbe-Hofmann N; Schlange T; Moldenhauer G; Altevogt P
    Cell Mol Life Sci; 2012 Nov; 69(22):3863-79. PubMed ID: 22760497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
    Azijli K; Yuvaraj S; Peppelenbosch MP; Würdinger T; Dekker H; Joore J; van Dijk E; Quax WJ; Peters GJ; de Jong S; Kruyt FA
    J Cell Sci; 2012 Oct; 125(Pt 19):4651-61. PubMed ID: 22797920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
    Birle DC; Hedley DW
    Cancer Res; 2007 Feb; 67(4):1735-43. PubMed ID: 17308115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SRC signaling is crucial in the growth of synovial sarcoma cells.
    Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-o-acetylbritannilactone (ABL) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling.
    Zhengfu H; Hu Z; Huiwen M; Zhijun L; Jiaojie Z; Xiaoyi Y; Xiujun C
    Biochem Biophys Res Commun; 2015 Aug; 464(2):422-7. PubMed ID: 26102035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
    Hennequin LF; Allen J; Breed J; Curwen J; Fennell M; Green TP; Lambert-van der Brempt C; Morgentin R; Norman RA; Olivier A; Otterbein L; Plé PA; Warin N; Costello G
    J Med Chem; 2006 Nov; 49(22):6465-88. PubMed ID: 17064066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.